AI-generated · cited to primary sources · not investment advice
Johnson & Johnson Common Stock (JNJ) Jun 2024 Filing Analysis
Where does growth come from?
The Cardiovascular franchise is showing accelerating operational growth, jumping from 18.0% in Q2 to 20.2% for the first six months of 2024. This is heavily driven by the acquisition of Shockwave Medical and strong adoption of the Impella heart pump line. (1 accelerating across 1 signal)
“Cardiovascular franchise... achieved operational sales growth of 18.0% as compared to the prior year fiscal second quarter... Electrophysiology grew by double digits due to global procedure growth, new product uptake and commercial execution.”
See the full cited Future Growth analysis of Johnson & Johnson Common Stock
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.